ACAAI COVID-19 VACCINE COMPARISON CHART – 5/13/21

Vaccine	Pfizer-BioNTech	Moderna	J&J Vaccine
Mechanism of	Vaccine contains 30 mcg of a	Vaccine contains 100	Replication-
action	nucleoside-modified	mcg of nucleoside-	incompetent
	messenger RNA (mod RNA)	modified messenger	adenovirus type 26
	encoding the viral spike (S)	RNA (mRNA) encoding	(Ad26)- vector
	glycoprotein of SARS-CoV-2	the pre-fusion stabilized	vaccine encoding a
		Spike glycoprotein (S) of	stabilized variant of
		SARS-CoV-2 virus.	the SARS-CoV-2 S
			protein
Dose	0.3 ml	0.5 ml	0 .5 ml
Schedule	2 doses ,21 days apart	2 doses, 28 days apart	1 dose
Storage	1. Vials must be kept frozen	1.Vaccine multiple-dose	1.Stored at 2°C to
	between -80°C to -60°C (-	vials are stored frozen	8°C (36°F to 46°F)]
	112°F to -76°F) and protected	between -25° to -15°C (-	in a multi-dose vial
	from light.	13° to 5°F protected from	containing 5 doses,
	2.If an ultra-low temperature	light, .	protected from light.
	freezer is not available, the	2.Do not store on dry ice	2.Unpunctured vials
	thermal container may be	or below -40°C (-40°F).	may be stored
	used as temporary storage	3. Vials can be stored	between 9°C to 25°C
	3. Thaw and then store	refrigerated between 2°	(47°F to 77°F) for up
	undiluted vials in the	to 8°C (36° to 46°F) for	to 12 hours.
	refrigerator [2°C to 8°C (35°F	up to 30 days prior to	2. After withdrawal
	to 46°F)] for up to 5 days	first use.	of first dose, the vial
	(120 hours)	4.Unpunctured vials may	should be held
	4 For immediate use, thaw	be stored between 8° to	between 2° to 8°C
	undiluted vials at room	25°C (46° to 77°F) for up	(36° to 46°F) for up
	temperature [up to 25°C	to 12 hours.	to 6 hours or at room
	(77°F)] for 30 minutes.	5. After the first dose has	temperature for up to
	5. Undiluted vials may be	been withdrawn, the vial should be held between	2 hours.
	stored at room temperature for no more than 2 hours.	2° to 25°C (36° to 77°F).	
	for no more than 2 nours.	Discard vial after 6	
		hours. Do not refreeze	
Age approved	12 and up	18 and up	18 and up
Efficacy against	7 days after second dose.	14 days after second	28 days after dose
Moderate to	18 -64 years- 95.1%	dose.	18- 59 years – 66.1%
Severe	65 years and above 94.7%	18 - < 65 years – 95.6 %	>60 years – 66.2 %
COVID19		>65 years - 86.4 %	USA 72.0%
			South Africa 64.0%
			Brazil 68 .1 %
VAERS	Mandatory Reporting of	Mandatory Reporting of	Mandatory
	adverse events Including	adverse events including	Reporting of adverse
	MIS, hospitalization/ fatal	MIS, hospitalization/	events including
	COVID	fatal COVID	

ACAAI COVID-19 VACCINE COMPARISON CHART – 5/13/21

			MIS, hospitalization/ fatal COVID
Safety Patient self-reporting	Vsafe	Vsafe	Vsafe
Adverse events			
Solicited adverse reactions within 7 days after each	Lasted 2-3 days, more adverse reactions after second dose	Lasted 2-3 days, more adverse reactions after second dose	(%) Pain 48.6% Erythema 7.3
dose.	Dose (%) 1 2 Pain at site 83.1. 77.98 Fatigue 47.4 59.4 Headache 41.9 51.7 Myalgia 21.3 37.3 Chills 14.0 35.1 Arthralgia 11.0. 21.9	Dose (%) 1 2 Pain at site 86.9. 89.9 Fatigue. 38. 67.6 Headache 24.5. 19.3 Myalgia. 23.7 61.6 Chills 9.2. 8.6 Arthralgia 16.6 45.5	Swelling 5.3 Headache 38.9 Fatigue 38.2 Myalgia 33.2 Nausea 14.2 Fever 9.0
Unsolicited	12 cases of appendicitis reported Anaphylaxis -reported after EUA with first dose	a). 3 cases of Bell's palsy reported 22,28, 32 days after vaccination – b). 2 cases Facial swelling in vaccine recipients with history of dermatological fillers in 1-2 days c). 1 case of nausea, vomiting 1 day after vaccination d) allergic reaction being investigated after EUA with first dose e) large local vaccine site reaction onset after day 7/8	a) embolic and thrombotic events-0.06% of vaccine recipients b) Tinnitus was reported in 6 vaccine recipients c) angioedema 0.2% of vaccine recipients d) urticaria e) arthritis 0.5% f)) peripheral neuropathy 0.2%
Ingredients	1. Lipids - 0.43 mg (4-hydroxybutyl) azanediyl), bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 0.05 mg 2[(polyethylene glycol)-2000], N,N-ditetradecylacetamide, 0.09 mg 1,2-distearoyl-sn-glycero-3-phosphocholine, 0.2 mg cholesterol) 2. 0.01 mg potassium chloride, 3.0.01 mg monobasic potassium phosphate	1. Lipids- 1.93 mg (SM-102, polyethylene glycol [PEG] 2000,dimyristoyl glycerol [DMG], cholesterol,1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]) 2. 0.31 mg tromethamine, 3. 1.18 mg tromethamine hydrochloride, 4043 mg acetic acid, 0.12 mg sodium acetate 5.43.5 mg sucrose.	1. Polysorbate 80 2. Citric acid mono hydrate 3. Trisodium citrate dihydrate 4. Hydroxypropyl Sodium chloride 5. Sodium hydroxide 6. Hydrochloric acid

ACAAI COVID-19 VACCINE COMPARISON CHART – 5/13/21

4. 0.36 mg sodium chloride	
5. 0.07 mg dibasic sodium	
phosphate dihydrate,	
6. 6 mg sucrose	